SCD and fatty liver disease: Previous research revealed that, CAY10566 (an SCD1-specific inhibitor)-treated HFD-fed mice exhibited significantly decreased hepatic steatosis and hepatic lipid droplet accumulation, as well as enhanced AMPK activity and lipophagy (Zhou et al. 2020).